Regeneron Pharmaceuticals Inc Director Bonnie Bassler Sells Company Shares
Director Bonnie Bassler has sold 827 shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on January 30, 2024, according to a recent SEC Filing. Over the past year, the insider has sold a total of 6,230 shares of the company and has not made any purchases of the stock.
Regeneron Pharmaceuticals Inc is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company's products include treatments for eye diseases, high LDL cholesterol, atopic dermatitis, asthma, and cancer.
The insider transaction history at Regeneron Pharmaceuticals Inc shows a pattern of insider selling, with 46 insider sells and no insider buys over the past year.
On the date of the insider's recent transaction, shares of Regeneron Pharmaceuticals Inc were trading at $959, giving the company a market cap of $104.347 billion. The price-earnings ratio stood at 27.32, which is slightly lower than the industry median of 27.94 but higher than the company's historical median price-earnings ratio.
According to the GuruFocus Value assessment, with a stock price of $959 and a GF Value of $716.82, Regeneron Pharmaceuticals Inc has a price-to-GF-Value ratio of 1.34, indicating that the stock is Significantly Overvalued.
The GF Value is calculated considering historical trading multiples, a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
